Elbasvir/Grazoprevir Experience - A New Glance at HCV Treatment: Case Report

ÇELEN M. K., Akdemir İ., TEKİN R., Bayan K., AYAZ C.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.23, sa.1, ss.34-36, 2017 (ESCI, TRDizin) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/vhd.10337
  • Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.34-36
  • Anahtar Kelimeler: Hepatitis C virus, oral antiviral treatment, elbasvir/grazoprevir, HEPATITIS-C VIRUS, TRIAL, EFFICACY, SAFETY
  • Ankara Üniversitesi Adresli: Hayır

Özet

Hepatitis C is a viral disease having a worldwide importance and posing a risk for liver complications. With the new treatment options, it is easy to manage with higher rates of success. Among them, one of the most recent one is elbasvir/grazoprevir option. This study presents the results of two treatment-naive patients treated with elbasvir/grazoprevir. The first case was a male non-cirrhotic patient and the second one was a female who suffered from compensated hepatic cirrhosis. Both patients received elbasvir/grazoprevir 50/100 mg in a single tablet for 12 weeks. Persistent viral response was achieved in both patients and no side effect was observed during the treatment. Elbasvir/grazoprevir combination, one of the recent treatments, was considered effective and tolerable.